Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis as Part of the 307 Open-Label Extension Study (EBMT 2023 PNH) - Apellis Medical Hub

Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis as Part of the 307 Open-Label Extension Study

Share Via Email

Back to Conference Resources

PNH Congress Presentations European Society for Blood and Marrow Transplantation 2023

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.